en POLSKI
eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank


 
3/2008
vol. 46
 
Share:
Share:
more
 
 
abstract:

REVIEW PAPER
Adalimumab – the first fully human monoclonal antibody used in the treatment of rheumatoid arthritis

Jacek Szechiński
,
Sławomir Jeka
,
Krzysztof Borysewicz
,
Anna Filipowicz-Sosnowska
,
Katarzyna Kolossa
,
Eugeniusz J. Kucharz
,
Beata Nowak
,
Jerzy Świerkot
,
Piotr Wiland

Reumatologia 2008; 46, 3: 151–158
Online publish date: 2008/07/09
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Rheumatoid arthritis is a systemic inflammatory disease leading to joint deformation and multiorgan dysfunction. Adalimumab belongs to a new class of antirheumatic drugs. This article gives a systematic review of data supporting the efficacy of adalimumab in the treatment of rheumatoid arthritis.
keywords:

adalimumab, rheumatoid arthritis







Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.